A Study of Renal Function Abnormalities in Patients with HIV Infection/AIDS by Premkumar, K
 
 
A STUDY OF RENAL FUNCTION ABNORMALITIES IN 
PATIENTS WITH HIV INFECTION /AIDS 
 
 
 
 
CROSS SECTIONAL STUDY 
 
 
 
 
 
                                             Dissertation Submitted for 
 
 
MD Degree (Branch I) General Medicine 
March- 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Tamilnadu Dr.M.G.R.Medical University 
Chennai – 600 032. 
 
 
 MADURAI MEDICAL COLLEGE, MADURAI. 
 
 
 
CERTIFICATE 
 
                             This is to certify that this dissertation titled “A STUDY  
OF RENAL FUNCTION ABNORMALITIES IN PATIENTS WITH  
HIV INFECTION /AIDS” submitted by DR. K.PREMKUMAR to the 
faculty of General Medicine, The Tamil Nadu Dr. M.G.R. Medical 
University, Chennai in partial fulfillment of the requirement for the 
award of MD degree branch I General Medicine, is a bonafide research 
work carried out by him under our direct supervision and guidance. 
 
 
 
 
DR.V.T.PREM KUMAR M.D .,              DR.A.AYYAPPAN M.D., 
Professor of Medicine,        Professor and Head, 
Chief, VII Medical Unit,                    Department of Medicine, 
Department of Medicine,       Madurai Medical College, 
Madurai Medical College,                Madurai. 
Madurai.  
 
 
  
                                        DECLARATION 
 
 
              I,  Dr.K.Premkumar  solemnly declare that the dissertation 
titled “A STUDY OF RENAL FUNCTION ABRNORMALITIES IN 
PATIENTS WITH HIV INFECTION AND AIDS”- CROSS 
SECTIONAL STUDY has been prepared by me. 
               This is submitted to the Tamil Nadu, Dr. M.G.R. Medical 
University Chennai, in partial fulfilment of  the requirement for the  
award of  MD degree Branch I (General Medicine). 
 
 
 
 
 
 
 
 
Place : Madurai                                      
 
Date:        Dr.K.Premkumar 
 
                    
  
 
ACKNOWLEDGEMENT 
 
                 I express my sincere thanks to The Dean, Govt. Rajaji 
Hospital and Madurai Medical College for permitting me to use the 
facilities of Madurai Medical College and Govt. Rajaji Hospital to 
conduct this study. 
       I will ever remain in gratitude to my chief        
Dr.V.T.Premkumar M.D., Prof of Medicine, not only for guiding me 
throughout the study, but also for being my mentor and source of 
inspiration during the period of my post graduate training. 
I express my sincere thanks to Our professor and Head of the 
Deparment  ofMedicine ProfDr.A.AyyappanM.D.,     beloved     teachers 
Dr.M.KamarajM.D., Dr.MosesKDanielM.D.,  Dr.S.Vadivel Murugan 
M.D.,    Dr.D.D.VenkatramanM.D.,        Dr.M.MuthiahMD.,   
Dr.P.ThirumalaikolundusubramanianM.D.,  Dr.NaliniGanesh M.D.,  
Dr. P.Selvaraj M.D., I owe them a lot and sincerely thank them. 
 
I express my sincere thanks to Prof Dr. Nagarajan MD, Professor 
and Head , Dept. of Sexually Transmitted diseases and Asst.Prof.Dr.M. 
Subramania Adithiyan MD, for their valuable guidance throughout the 
study.  
I express my heartfelt thanks to my Assistant Professors 
Dr.Ganesapandian M.D., Dr.V.N.Alagavenkatesan M.D., for their 
valuable support and guidance. 
 
           I express my sincere thanks Medical Officer in Anti Retroviral 
Therapy Centre Dr.P.Jayakumar, and also staffs in the ART centre 
S.Prabhu, V.Raja Mahendravarman, A.Inigo Beulah, V.C. Pitchai, 
P.Aruna, M.Umadevi for their valuable support throughout my study. 
 My family and friends have stood by me during my times of need. 
Their help and support have been valuable to the study. 
 
I would grossly fail in my duty if I fail to mention here of my 
patients who have ungrudgingly borne the pain and discomfort of 
investigations. I cannot but pray for their speedy recovery and place this 
study as a tribute to them and to the numerous others likely affected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONTENTS 
S NO.  CONTENTS    PAGE NO 
1.    INTRODUCTION     1  
2.   REVIEW OF LITERATURE                        10 
3.    AIMS AND OBJECTIVES                          44 
4.   MATERIALS AND METHODS                 45 
5.   RESULTS AND OBSERVATIONS           48 
6.   DISCUSSION AND COMPARATIVE  
 ANALYSIS                           56                        
7.   CONCLUSION            62 
8.   SUMMARY                                                 63 
 
    APPENDIX 
BIBLIOGRAPHY 
GLOSSARY 
PROFORMA 
MASTER CHART 
ETHICAL COMMITTEE APPROVAL FORM 
                                    
 
 1 
 
                             INTRODUCTION 
HUMAN IMMUNODEFICIENCY VIRUS DISEASE 
           AIDS was first recognized in the United States in 1981, when the U.S. 
Centers for Disease Control and Prevention (CDC) reported the unexplained 
occurrence of Pneumocystis jiroveci (formerly P. carinii) pneumonia in five 
previously healthy homosexual men in Los Angeles and of Kaposi's sarcoma 
(KS) with or without P. jiroveci pneumonia in 26 previously healthy 
homosexual men in New York and Los Angeles. Within months, the disease 
became recognized in male and female injection drug users (IDUs) and soon 
thereafter in recipients of blood transfusions and in hemophiliacs. Then it 
became clear that an infectious agent transmissible by sexual (homosexual 
and heterosexual) contact and blood or blood products was the most likely 
etiologic cause of the epidemic.[ref1] 
In 1983, human immunodeficiency virus was isolated from a patient with 
lymphadenopathy, and by 1984 it was demonstrated clearly to be the 
causative agent of AIDS. In 1985, a sensitive enzyme-linked immunosorbent 
assay (ELISA) was developed, which led to an appreciation of the scope and 
evolution of the  epidemic at first in the United States and other developed 
nations and ultimately among developing nations throughout the world .  
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DEFINITION 
 Using the current CDC3 classification, any HIV infected individuals with 
a CD4+ T cell count of < 200/µL has AIDS by definition, regardless of the 
presence or absence of symptoms or opportunistic diseases.[ref1]                                       
EPIDEMIOLOGY 
HIV infection/AIDS is a global pandemic, with cases reported 
from virtually every country. At the end of 2007, 33.2 million individuals 
were living with HIV infection (range: 30.6–36.1 million) according to 
the Joint United Nations Programme on HIV/AIDS (UNAIDS). More 
than 95% of people living with HIV/AIDS reside in low- and middle-
income countries; ~50% are female, and 2.5 million are children .[ref1] 
                   In 2007, there were an estimated 2.5 million new cases of HIV 
infection worldwide, including 420,000 in children <15 years. In 2007, 
global AIDS deaths totaled 2.1 million (including 330,000 children <15 
years). UNAIDS estimates that global HIV prevalence has been level since 
2001. incidence likely peaked in the late 1990s at >3 million new infections 
per year . Recent reductions in global HIV incidence likely reflect natural 
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trends in the pandemic as well as the results of prevention programs resulting 
in behavior change.[ref1] 
                 HIV prevalence in India is~3.6% amounting between 2 and 3.1 
million people. On an average it comes to 2.5 million. The prevalence for 
adult female is 0.29% and for males 0.43%. Prevalence high in age group 
15- 49 years. [ref2]   Among IDU’s it is as high as 8.71% while it is 5.69% 
and 5.38% among MSM and FSW respectively.[ref2]                     
In    AndhraPradesh Karnataka, Maharasthra and Tamilnadu HIV is 
transmitted mainly through heterosexual route and is largely linked to 
commercial sex work. Indeed, according to selected surveys more than half 
of sex workers have become infected with HIV.  
In India knowledge about HIV is still scant and incomplete. In a 2001 
national behavioral study of nearly 85000 people, only 75% of respondents 
had heard of AIDS and awareness was particularly low among rural women 
in Bihar, Gujarat and West Bengal. Less than 33% of all respondents had 
heard of sexually transmitted infections and only 21% were aware of the 
links between sexually transmitted infections and HIV.  
The etiologic agent of AIDS is HIV ,which belongs to the family of Human 
\retroviruses (Retroviridae) and the subfamily of lentiviruses. The HIV 
virion is an icosahedral structure containing numerous external spikes 
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formed by the two major envelope proteins ,the external gp120 and the 
transmembrane gp41. 
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 TRANSMISSION 
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                 HIV is tranmitted by both homosexual and heterosexual contact; 
by blood and blood products and by infected mother to infants  either  
intrapartum, perinatally or via breastmilk. 
PATHOPHYSIOLOGY AND PATHOGENESIS 
The hallmark of  HIV disease is a profound immunodeficiency resulting 
primarily from a progressive quantitative deficiency of the subset of T 
lymphocytes referred to as helper T cells. When the number of CD4+ cells 
declines below a certain level, the patient is at high risk of developing a 
variety of opportunistic diseases, particularly the infections and neoplasms 
that are AIDS- defining illnesses. Some features of AIDS, such as KS and 
neurologic abnormalities cannot be explained completely by the 
immunosuppressive effects of HIV ,since these complications may occur 
prior to the development of severe immunologic impairment.  
The combination of viral pathogenic and immunopathogenic events that 
occurs during the course of HIV disease from the moment of initial 
(primary) infection through the development of advanced stage disease is 
complex and varied. It is important to appreciate that the pathogenic 
mechanisms of HIV disease are multifactorial and multiphasic.[ref1] 
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ANTIRETROVIRALTHERAPY     
               The best time to initiate antiretroviral treatment (ART) remains 
controversial. It is best to weigh the benefits of viral suppression against side 
effects of the drugs for each patient. In general, treatment for asymptomatic 
HIV disease should be initiated when the CD4 cell count drops below 350 
cells/micL or symptomatic HIV disease. Patients with rapidly dropping CD4 
counts or very high viral loads (>100,000/micL) should be considered for earlier 
treatment. For these patients who might have difficulty adhering to treatment or 
who are at higher risk for toxicity (eg. Underlying liver disease), waiting until 
the CD4 count nears 200 cells/micL may be a better strategy. 
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Antiretroviral  Drugs Used in the Treatment of HIV Infection 
Drug Toxicity 
Zidovudine (AZT) Anemia, granulocytopenia, myopathy, lactic acidosis, hepatomegaly 
with steatosis, headache, nausea 
Didanosine (ddI) Pancreatitis, peripheral neuropathy, abnormalities on liver function 
tests, lactic acidosis, hepatomegaly with steatosis 
Zalcitabine (ddC) Peripheral neuropathy, pancreatitis, lactic acidosis, hepatomegaly 
with steatosis, oral ulcers 
Stavudine (d4T) Peripheral neuropathy, pancreatitis, lactic acidosis, hepatomegaly 
with steatosis, ascending neuromuscular weakness, lipodystrophy 
Lamivudine (3TC) Hepatotoxicity 
Emtricitabine Hepatotoxicity 
Abacavir Hypersensitivity reaction (can be fatal); fever, rash, nausea, 
vomiting, malaise or fatigue, and loss of appetite 
 
Tenofovir Potential for renal toxicity 
Delavirdine Skin rash, abnormalities in liver function tests 
Nevirapine Skin rash, hepatotoxicity 
Efavirenz (Sustiva) 
 
Rash, dysphoria, elevated liver function tests, drowsiness, abnormal 
dreams, depression 
Etravirine Rash, headache, dizziness, nausea, diarrhea 
Saquinavir mesylate Diarrhea, nausea, headaches, hyperglycemia, fat redistribution, lipid 
abnormalities 
Fortovase Diarrhea, nausea, abdominal pain, headaches, hyperglycemia, fat 
redistribution, lipid abnormalities 
Ritonavir Nausea, abdominal pain, hyperglycemia, fat redistribution, lipid 
abnormalities, may alter levels of many other drugs, including 
saquinavir 
 
Indinavir sulfate Nephrolithiasis, indirect hyperbilirubinemia, hyperglycemia, fat 
redistribution, lipid abnormalities 
Nelfinavir mesylate May contain traces of the potential carcinogen/teratogen ethyl 
methane sulfonate 
Amprenavir Nausea, vomiting, diarrhea, rash, oral paresthesias, elevated liver 
function tests, hyperglycemia, fat redistribution, lipid abnormalities 
Fosamprenavir  
Lopinavir/ritonavir Diarrhea, hyperglycemia, fat redistribution, lipid abnormalities 
Atazanavir Hyperbilirubinemia, PR prolongation, nausea, vomiting, 
hyperglycemia, fat maldistribution 
Tipranavir Diarrhea, nausea, fatigue, headache, skin rash, hepatotoxicity, 
intracranial hemorrhage 
Darunavir Diarrhea, nausea, headache 
Enfuvirtide Local injection reactions, hypersensitivity reactions, increased rate of 
bacterial pneumonia 
Maraviroc Hepatotoxicity, nasopharyngitis, fever, cough, rash, abdominal pain, 
dizziness, fever, musculoskeletal symptoms 
Raltegravir Nausea, rash 
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REVIEW OF LITERATURE 
Introduction  
 The renal manifestations of HIV infection occurs commonly during
all stages of infection.  Renal Manifestations of HIV infection occurs in 6-
10% of HIV seroperative individuals . Fluid, electrolytes and acid-base,
abnormalities, as well as acute renal failure, have been observed frequently,
mainly as a consequence of drug toxicity or opportunistic infections .  
Disorders of kidney may be due to  
- a direct of consequence of HIV infection  
- neoplasm  
- related to drug toxicity  
 The most clinically relevant disorder is chronic renal failure
progressing to end stage renal disorder (ESRD), which has also been
observed with a high frequency in some centers. Caused by HIVAN - HIV
associated immune mediated renal disease . 
 The progression of HIV disease is more rapid in patients with renal
failure, particularly those with pre-existing end-stage renal disease who
become infected with HIV as a result of hemodialysis or renal
transplantations. [ref4] 
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  The susceptibility of blacks, men, and persons with a H/o IDU suggests both 
genetic and environmental factors may modulate the development of HIV-
associated renal disease.  
1. Classification[ref5] 
2. Acute renal failure and fluid & electrolyte disorders  
i. Acute renal failure  
ii. Disorders of osmoality  
iii. Potassium disorders  
iv. Acid-base disorders  
3. Glomerular renal disease  
4. HIV associated nephropathy  
i. Other renal lesions  
ii. End stage renal disease  
II. Acute renal failure and fluid and electrolyte disorders  
(i) Acute renal failure  
III. Causes  
5. Prerenal:  
1. Volume depletion – Diarrhoea  
I. Bleeding 
II. Decreased intake   
III. NSAID’s  
2. Sepsis 
3. Early obstructive uropathy  
(A) Renal: 
1. Acute tubular Necrosis:  
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  - Ischemia / hypoperfusion  
  - Sepsis/endotoxemia  
  - Radiocontrast exposure  
  - Nephrotoxic antibiotics  
   Amphotericin B,  
   Aminoglycosides  
   Pentamidin  
   Foscarnet  
   Acyclovir  
   Cidofovir  
   Tenofovir  
2. Acute interstitial nephritis  
  - Sulfamethxazole  
  - Dapsone  
  - NSAIDs  
  - Rifampin  
3. Glomerular disease  
  - HIVAN  
- HCV – MPGN (Mesangio proliferative glomerulo  
   nephritis) 
- other primary glomerulo nephropathies  
       4. Infiltrative lesions  
   - Kaposis sarcoma  
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   - Renal cell carcinoma  
   - Lymphoma  
   - Amyloidosis  
       5. Vasculitis    
   - Hemolytic – uremic syndrome  
   - Thrombotic – thrombocytopenic purpura  
   - renal cortical infarction  
        6. Systemic infections  
   - Mycobacterium species 
   - Candida species  
   - Cryptococcus species  
   - Aspergillosis  
   - Cytomegalovirus  
   - Bacterial endocarditis  
   - Renal microabscess formation  
    7. Miscellaneous  
   HAN (Heroin associated nephropathy)  
   Nephrosarca (renal oedema with severe  
hypoalbuminemia) 
Chemical interference with the creatinine assay  
Trimethoprim – sulfamethoxazole 
Cephalosporins  
Cimetidine  
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(B) Post Renal / Obstruction  
1. Drugs causing crystalluria  
Sulfadiazine  
Indinavir  
Acyclovir  
2. Malignancy  
Mild ARF: Defined as a peak serum creatinine >=2.0mg/dl. Occurs in upto 
20% of hospitalized HIV infected patients . This percentage compares to an 
incidence rate of 4-5% in hospitalized non-HIV infected patients [ref5]. 
Patients with ARF on admission to the hospital are likely to have a prerenal 
cause related to hypovolemia. In patients who develop during the 
hospitalization, the likely cause is acute tubular necrosis from hypotension or 
drug nephrotoxicity. Common causes of ATN include sepsis, hypotension, 
and medications commonly used in the treatment of HIV-related infections 
such as aminoglycosides, pentamidine, acyclovir, foscarnet, amphotenicin B, 
tenofovir, adefovir and cidofovir, NSAIDs, rifamicin, trimethoprim – 
sulfamethoxazole . Both foscarnet and tenofovir are associated with 
development of nephrogenic diabetes insipidus. 
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Severe Renal Failure:  
 In HIV infected patients, sepsis contributes to the development of severe 
renal failure, defined as a peak creatinine >=6.0mg/dL, in upto 75% of cases 
severe renal failure in HIV –infected patients may be associated with 
terminal conditions in which acute dialysis would be inappropriate.  
When the acute underlying illness is reversible, however, ARF will 
usually reverse with dialysis and conventional supportive care. Because the 
overall prognosis is favourable .  
Acute interstitial nephritis has been found in 13% of autopsies done in 
patients with renal dysfunction, and an inciting agent is usually not identified 
[ref5]. 
Obstructive uropathy may be the result of abdominal adenopathy or 
sludge formation in the collecting system due to crystallization of protease 
inhibitors and Acyclovir. Rare opportunistic infections such as isolated renal 
mucormycosis, have also been described . 
Renal function generally is restored once rigorous hydration is 
administered and the inciting agent is discontinued.  
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Reversible causes of renal insufficiency  
 Kidney infection  
 Exposure to nephrotoxic antibiotics or radiologic contrast  
 Endotoxemia  
 Hypoperfusion  
Progressive renal insufficiency  
 Result from parenchymal infiltration with Kaposisarcoma or lymphoma.  
Urinalysis is extremely helpful in differential diagnosis of ARF in HIV 
patients. Urine sediment should be  
(1) prerenal patients - normal   
(2) ATN - muddy brown, granular casts and/or renal tubular cells and 
casts.  
(3) Ac. Interstitial nephritis - predominately show WBCs, WBC casts, 
and a small amount of proteinuria and hematuria.  
(ii) Disorders of Osmolality: 
 Among the electrolyte abnormalities observed in HIV patients, two-
hyponatremia and hyperkalemia – are of most significance. [ref6] 
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Hyponatremia: 
1) Most common electrolyte disturbance  
2) Have been reported in 30-60% of hospitalized symptomatic HIV patients 
or AIDS and  
3) Severe hyponatremia may be associated with increased morbidity and 
mortality in HIV infected patients  it is a poor prognosis.  
4) Volume depletion due to diarrhoea or vomiting is the usual cause of 
hyponatremia present at the time of hospital admission. In most of cases, 
when normal ECF volume is restored, the hyponatremia is corrected .  
5) Excess body water is attributed either to hypovolemia with physiologic 
stimulation of ADH, administration of hypotonic fluids, or the SIADH. 
SIADH is the likely culprit in those who develop hyponatremia during 
hospitalization .  
SIADH is usually associated with common pulmonary and intracranial 
diseases, such as  
- Pneumocystis pneumonia,  
- toxoplasmosis and  
- Tuberculosis  
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Plasma ADH concentration, when measured in some of these patients, has 
been inappropriately elevated for the degree of hyponatremia and hypo-
osmolality lending strong support for this being the mechanism underlying 
the hyponatremia .[ref7] 
6) The initial treatment of SIADH consists of fluid restriction and treatment 
of underlying infection or malignancy.  
7) In a few patients, evidence of adrenal insufficiency has accompanied the 
hyponatremia, and treatment with glucocorticoid hormone has improved the 
serum sodium concentration .  
AIDS patients have a high incidence of adrenal abnormalities. Adrenal 
pathology, particularly CMV infection is found common in patients who 
have died from AIDS .  
Other pathologic lesions that have been noted frequently include 
hemorrhage;  
infection with toxoplasma,  
Cryptococcus,  
mycobacterium tuberculosis,  
MAC;  
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infiltration with kaposi’s sarcoma and lymphoma .  
Several drugs that are used commonly in the treatment of patients with 
AIDS are known to alter adrenal function or steroid hormone metabolism.  
 
1. Ketaconazole inhibits cortisol synthesis and could lead to adrenal 
insufficiency, particularly in patients with limited adrenal reserve.  
2. Rifampin enhances cortisol metabolism, which can result in adrenal 
insufficiency in patients with Addison’s disease who are on maintenance 
gluocorticoid therapy.  
(iii) Potassium Disorders 
 Both hypokalemia and hyperkalemia commonly develop in HIV infected 
patients.  
 Hypokalemia is predictably seen secondary to gastrointestinal losses of 
potassium in HIV patients with gastrointestinal infections.  
 Amphotericin-B, frequently used to treat fungal infections in patients 
with AIDS can cause tubular dysfunction resulting in hypokalemia.  
Hyperkalemia may occur as a result of the effect of  
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1) High doses of trimethoprin – sulfamethoxazole or IV pentamidine.  
The underlying mechanism with both drugs consists of inhibition of distal 
nephron sodium transport, leading to a decrease in distal protein secretion .  
Trimethoprim shares structural similarity with the potassium sparing diuretic 
triamterene.  
2) Hyperkalemia and hyponatremia may also be a manifestation of 
mineralocorticoid deficiency due to adrenal insufficiency or the syndrome of 
hyporeninemic hypoaldosteronism .  
3) Severe acute or chronic renal insufficiency may also contribute to 
the development of hyperkalemia due to potassium retention. Treatment of 
hyperkalemia should be guided by the cause and severity; it should respond 
to cessation of offending drugs or to treatment with loop diuretics or with 
fludrocortisone for adrenal causes .  
A systemic abnormality in potassium equilibrium, which favours the 
development of hyperkalemia by a mechanism unrelated to renal potassium 
excretion, has also been identified in HIV – infected individuals .  
(iv) Acid Base Disorders  
 HIV patients may present with a variety of simple and mixed acid-base 
disorders. Commonly due to infections or drugs.  
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 Respiratory alkalosis and respiratory acidosis may occur in opportunistic 
infections of the lungs or CNS. Both high and non anion gap metabolic 
acidosis are also seen.  
Causes of non anion gap metabolic acidosis [ref5] 
-             Stool base losses from diarrhoea  
-              adrenal insufficiency  
-              the syndrome of hyporeninenic hypoaldosteronism,  
-              drug toxicity (Amphotericin B – related renal tubular acidosis)       
 High anion gap metabolic acidosis in this population results from  
-              CRF  
-             Type A lactic acidosis due to tissue hypoxia (sepsis)  
-             Type B lactic acidosis  
 Type B lactic acidosis presents with markedly elevated blood lactate 
levels possibly caused by drug-induced mitochondrial dysfunction –
“Mitochondrial myopathy” causing in interruption of normal mitochondrial 
respiration in skeletal muscle. This disorder been reported with .  
Zidovudin  
Didanosin  
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Zalcitabine  
Lamivudin  
Stavudin  
 These patients have no evidence of hypoxemia, tissues hypoperfusion, 
malignancy or sepsis. Recognition of this entity rests with a severe metabolic 
acidosis with an increased anion gap; blood lactate levels when measured, 
have been greater than 5, and frequently greater than 10 mmol/l . 
 Although life threatening acidosis is rare, 5-25% of treated patients may 
develop mildly elevated lactate level (2.5-5mmol/L) without acidosis.  
 Survival is shortened in these patients .  
III GLOMERULAR RENAL DISEASE  
(A) HIV associated Nephropathy (HIVAN)  
a. Epidemiology 
1. HIVAN is a unique clinical and histopathological entity and it is thought 
to develop as a result of HIV gene expression in renal tissue. HIVAN may be 
the initial manifestation of HIV infection.  
2. HIVAN was first described in IDUs and was initially thought to be IDU 
nephropathy in patients with HIV infection. The disease now recognized as 
HIVAN was first described in patients with AIDS in 1984. But the 
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occurrence of this lesion in infants and children with AIDS from vertical 
transmission indicates that drug use is not necessary for its development .  
3. HIVAN represents a major complication of HIV infection. Its natural 
history has been well defined – the development of nephrotic syndrome 
initially, then relentless progression to end-state renal disease (ESRD) in 
most patients [ref8].  
HIVAN has become the most common single diagnosis in HIV 
infected patients with renal insufficiency.  
The true prevalence of HIVAN is not known. HIVAN is more 
common in urban centres, with a prevalence of about 10%. The geographic 
distribution of HIVAN is not uniform, and depends on specific risk factors, 
which include race, gender, and drug use.  
HIVAN, worldwide, over 90% of reported cases have occurred in 
people of African descent as is also true for focal segmental 
glomerulosclerosis (FSGS) associated with intravenous drug use  (IVDU) .  
HIVAN is 7-10 times more common in men than women, men 
comprises 80 to 90%  of  cases   and 30-60% of people with HIVAN have a 
H/o IVDU . The remainders are either homosexual or originate from regions 
where HIV infection is endemic . In approximately 10% patients – no 
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specific risk factor for HIV can be identified . Black men have increased risk 
[ref4,9].  
Thus, in the United States, the typical patient with HIVAN is a young 
African American male with a H/o IVDU.  
Unfortunately, most patients who develop HIVAN do not have early 
signs or symptoms that would provide a clue to this diagnosis prior to the 
onset of progressive nephropathy.  
HIVAN is recognized throughout the spectrum of HIV disease.  
Clinical presentation typically includes  
- Proteinuria but no hematuria on urinalysis  
- high grade proteniuria, usually in nephrotic range (>3.5gms/day)  
Proteinuria is the hall mark of HIVAN. Over all, microalbuminuria is seen in 
~ 20% of untreated HIV infected patients; significant proteinuria is seen in 
closer to 2% [ref1] Hypoalbuminemia disproportionate to the degree of 
proteinuria.  
- Normal or large kidneys with increased echogenicity on diagnostic 
ultrasound.[ref10]. 
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- Note worthy is the rarity of hypertension and peripheral oedema in 
these patients despite the severity of the renal failures and proteinuria . 
Prognosis may depend on the clinical status of HIV infection, the presence 
of ESRD or both. [ref11]. 
- HIVAN has poor prognosis, most patients progress quickly to ESRD 
within 2 to 6 months.  
 Until the factors that precipitate HIVAN are identified and randomized 
drug trials performed, its therapy will remain empiric and be limited to 
suppression of viral proteins.  
b. Pathogenesis  
1. The pathogenesis of HIVAN has been studied intensely over the past 15 
yrs. A central question in the pathogenesis of HIVAN is whether the disease 
can be attributed to direct viral effects or to HIV related changes in the 
cytokine milieu. 
2. HIV appears to be trophic for specific cell types, including lymphocytes 
(T cells) and epithelial cells of colon, CNS and kidneys. The basis for 
tropism is complex and is not simply related to the presence of a surface CD4 
receptor on susceptible cells . 
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3. HIVAN is caused by HIV gene expression in renal tissue, resulting in 
injury of glomerular and tubular epithelial cells. This accounts for leakage of 
filtered proteins. (nephrotic syndrome) and renal failure.  
4. Since HIV proliferation appears to be the major determinant of 
cytotoxicity, factors that precipitate viral replication within the kidney could 
explain the sudden onset of the disease.  
5. HIV proliferation is regulated by at least two genes, nef and vif, with 
opposing action. Minor mutation in either of these could lead to rapid viral 
proliferation and death of the host cell.  Concomitant infection with viral 
hepatitis, syphilis or CMV, could induce HIV replication.  
6. CMV may promote viral proliferation through a mechanism that is 
dependent on tumor necrosis factor (TNF) .  
7. Concomitant viral infections might remove inhibition to HIV replication 
by depleting CD4 lymphocytes, further depressing the immuno system.  
8. HIV is a potent stimulator of transforming growth factor -β a cytokine 
strongly implicated in the development of fibrosis. The transgenic mouse 
model (Tg 26) suggests that activation of the cytokine could well be the 
basis for the extensive interstitial fibrosis and glomerular sclerosis that are 
the hall marks of HIVAN .  
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9. There are evidences to indicate a strong association between. HIV and 
HIVAN. HIV DNA and protein markers specific for HIV have been 
demonstrated in tubular epithelium, glomerular  epithelial cells, and 
mesangeal cells by a variety of techniques in vitro and in renal biopsy tissue 
of HIV patients . 
10. HIV DNA has also been identified in the tissue of HIV patients without 
any renal disease .  
11.  Studies with transgenic mouse model (Tg 26)showed HIVAN with intact 
vpr gene .the transgenic mice bearing a simplified proviral DNA (encoding 
tat and vpr )developed renal disease characterized by FSGS in which vpr 
protein was localized to glomerular and tubular epithelia by 
immunohistochemistry.[Virology vol 322,issue1,Apr2004]. 
12. HIV infection may involve epithelial cells from multiple segments of the 
nephron, including proximal tubule, thick ascending loop of Henle, and 
collecting duct. This pattern of involvement may explain the tubular 
dilatation seen in kidney biopsy specimens of patients with HIVAN . 
13.  Despite undetectable viral levels in the serum, a case report described a 
patient who continued to express HIV in renal epithelial cells as determined 
by RNA in situ hybridization .  Active replication of HIV occurs in kidney 
epithelium, possibly producing HIV strains in the kidney microenvironment, 
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that differ from HIV circulating in the blood. This suggests that kidney may 
serve as a viral reservoir harboring HIV strains that have evolved under 
tissue-specific selection pressures .  
(c) Clinical manifestation  
 Renal manifestations of HIV infection occurs in 6-10% of HIV 
seropositive individuals.  
 Proteinuria is the hall mark of this disorder. Most patients (89%) excreted 
1gm or more of protein / day .[ref12]. 
Clinical presentation of HIVAN  
Source: Adapted from JJ Bourgoignie, R.Meneses, C. Ortiz, et al.,  
PRESENTATION % OF PATIENTS 
Azotemia                      64 
Proteinuria                      19 
Azotemia &proteinuria                      9 
Electrolyte imbalance                      6 
Gross hematuria                      3 
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Features consistent with diagnosis of HIVAN include 
• Absence of hypertension  
• A characteristic urine sediment  
• Normal or large kidneys  
• Hypoalbuminemia disproportionate to the degree of proteinuria and 
rapidly progressive renal insufficiency. 
(d) Histopathology 
 HIVAN is associated with characteristic glomerular, tubulointerstitial  
and ultrastructural lesions. Autopsy data demonstrate that 90% of patients 
with the clinical diagnosis of HIVAN have focal and segmental 
glomerulosclerosis (FSGS).[ref12]. FSGS is a pattern of renal response to 
a variety of insults and is not specific for HIVAN. Renal biopsy may 
confirm the clinical diagnosis of HIVAN.  
Light microscopic features include 
• Collapsing focal segmental glomerulosclerosis or mesangial 
hyperplasia, a probable precursor lesion to FSGS 
• Cystic tubular dilatation;  
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• Interstitial odema;  
• Cellular infiltration by lymphocytes or monocytes;  
Dilated degenerating proximal tubules filled with eosinophilic material, 
possibly representing cast formation in situ.[ref13]. 
 Electron Microscopy 
 The presence of numerous tubuloreticular inclusions (TRI) within 
endothelial cells is another important finding in HIVAN . TRI’s are more 
common and more numerous in HIVAN than in HAN or idiopathic 
FSGS.[ref13]  
A more than 10-fold increase in the number of TRIs per glomerular 
capillary was noted in HIVAN. Finding numerous TRIs in capillary 
endothelial cells in a patient with FSGS prompts some pathologists to 
request HIV antibody testing.TRI’s may be a component of interferon or 
reflect a cellular response to interferon, but not represent particles of HIV.
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Although renal tissue may stain for IgM, C1q, C3 and Kappa or lamda 
light chains in areas of focal sclerosis, immunologic mechanisms are 
probably not central to genesis of HIVAN . Both immuno globulin and 
complement can be trapped nonspecifically by sclerosing glomeruli 
COLLAPSING FOCAL SEGMENTAL GLOMERULOSCLEROSIS 
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 (e) Investigations 
 Examination of urine sediment in HIVAN often reveals evidence of severe 
proteinuria with oval fat bodies and frank lipiduria.  Large number of broad 
(giant) waxy casts have also been observed in some patients.  
1. Proteinuria: Proteinuria is the hall mark of this disorder. Overall, 
microalbuminuria is seen ~20% of untreated HIV infected patients. 
Significant proteinuria is seen in closer to 2%.  Fever, exercise, 
hyperglycemia, and severe hypertension can transiently cause proteinuria. To 
precisely quantitate and qualitatively analyze the amount and composition of 
urinary proteins, an examination of a 24 hour collection of urine is usually 
required. The normal 24 hours urine protein executed in the adult ranges 
from 30 to 150 mg. children and adolescents may excrete as much as twice 
this amount. In HIVAN, nephrotic range proteinuria is usually seen (>3.5gm 
/ 24 hrs.). A urinary protein creatinine concentration ratio on the first voided 
morning urine sample is useful substitute for repeated 24 hours urine protein 
estimation. Normal spot urinary protein creatinine ratio on random samples 
generally fall below 2. Values >3 suggest the presence of nephrotic range 
proteinuria. Microalbuminuria indicates excretion of albumin of 20-200 µgm 
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per minute (albumin excretion rate of AER) of a daily excretion of albumin 
in the range of 30-300mg.  
2. The dramatic decline observed in serum albumin concentration  (to ≤ 
1gm /dl) with moderate albuminuria (<10gm/day) may be caused by 
malnutrition or a defect in hepatic albumin synthesis or both. But in HIVAN, 
hypoalbuminemia will be disproportionate to the degree of proteinuria.  
Serum Electrophoresis: (Proteins)  
Nephrotic syndrome  alb ↓  α2 Glo↑ 
Chronic liver disease  
with cirrhosis   alb ↓  γ Glo↑ 
Malnutrition   alb ↓   
Acute febrile illness  α1 ↑ 
Hyperlipidemia          β Glo ↑ 
3. Azotemia, proteinuria or both are the presenting feature in >90% of HIV 
infected patients.  
In HIVAN, progression to end-stage renal disease occurred in an average of 
1.9 weeks from the onset of mild azotemia .  
4. Renal Ultrasound in patients with HIVAN typically shows normal or 
enlarged renal silhouette (>12.3 cm) with increased echogenicity, even with 
advanced renal failure. [ref10]. 
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Renomegaly may be the result of  
– insufficient time for global sclerosis and fibrosis given the rapid 
progression of renal disease.  
– Marked dilatation of the tubules with numerous microcysts, in 
contrast to the tubular collapse frequently seen in other forms of chronic 
renal injury and interstitial oedema.  
5. Renal biopsy may confirm the clinical diagnosis of HIVAN. 
Histopathology has already been discussed earlier. Biopsy in HIV infected 
patients with proteinuria finds the typical features of HIVAN in about 60% 
of cases; and a variety of other disease entities are also found in association 
with factors such as hepatitis and drug use.  
 
Diagnosis in HIV infected patients with proteinuria  
• 60% have typical features of HIV associated nephropathy on biopsy Æ 
FSGS and microcystic tubulointerstitial disease.  
• Other common diagnosis  
- FSGS alone (additional 10% - 15%)  
- MPGN (10%)  
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- Tubulointerstitial disease (7%)  
- Minimal change disease (5%)  
- Membranous glomerulopathy (4%)  
- Lupus like nephritis (3%)  
- Amyloidosis (3%) [ref13]             
(f) Clinical course and Treatment  
 The clinical course of HIVAN is rapid  progression to ESRD in 6-12 
months [ref4] with limited treatment options which include 
• Anti retroviral therapy (ART) [ref14]. 
• Steroid treatment  
• ACE inhibitors (ACE-Is) [ref15]. 
(i) ART: Because of the possible direct role HIV in the pathogenesis 
of HIVAN, ART would be expected to have beneficial effects. There have 
been case reports of dramatic improvements in renal function with initiation 
of combination ART  but no prospective studies have shown a benefit in the 
course of HIVAN. Retrospective studies and case reports suggest that 
monotherapy with zidovudin may slow or even reverse the rapid 
deterioration associated with HIVAN . The AIDS Clinical Trials Group 
 37 
 
(ACTG) is currently developing a clinical trial  to compare treatment with an 
angiotensin receptor blocker (Valsartan) plus ART to ART alone in patients 
with HIVAN.  
(ii) Steroid Treatment: There is 20 to 40% response rate of 
corticosteroids. Prednisolone 60mg/day for 2 to 11 wks leads to a significant 
reduction in serum creatinine and 24-hours urine protein excretion  (due to 
reversal of interstitial inflammation) and 80% reduction in risk of 
progressive azotemia [ref1]. 
(iii) ACE – inhibitors: (Captopril and Fosinopril) Angiotensin II 
increases the cellular synthesis of transforming growth factor – beta (TGF- 
Beta) which has been implicated in the pathogenesis of HIVAN; ACE – 
inhibitors are effective in slowing the progression of renal insufficiency by 
reducing production of TGF-Beta in both humans and HIV-transgenic mice. 
Studies suggest that ACE-Is initiated early may offer renal survival benefits 
in HIVAN .  
(g) Current recommendations for treatment of HIVAN:  
 Renal biopsy should be offered to patients as the treatment implications 
and prognosis vary according to the biopsy results. 
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 Risk factors for progressive renal disease include  
- CD4 count <200 cells /µl [ref16]. 
- Detectable HIV RNA level  
- Hypertension  
- Low albuminemia  
- Elevated serum creatinine   
  Combination ART should be initiated early in these patients. Because 
serum viral loads do not necessarily reflect the severity or rate of progression 
of HIVAN .The degree of renal insufficiency should influence the choice 
and dose of individual antiretroviral agents.  
ACE-Is should certainly be the antihypertensive drug of choice in HIV 
infected patients with renal disease and hypertension, and should be 
considered in normotensive HIV infected patients with renal disease.  
The role of corticosteroid treatment remains controversial, but may be 
considered in patients with HIVAN and early HIV disease whose renal 
failure is progressing rapidly. 
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(B) Other Renal Lesions 
 HIVAN is rare in non-African Americans. HIV associated immune 
mediated renal disease is the most common glomerular disease found on 
renal biopsy in series reported from Italy and France . 
  The patterns of glomerular involvement seen in these patients include,  
- IgA nephropathy  
- Membranous nephropathy  
- Membrane proliferative GN  
- Mesangial proliferative GN  
- Diffuse proliferative GN 
- Crescentric GN  
Immune complex deposition in glomeruli leads to a proliferative 
glomerulonephritis and renal insufficiency. 
The important forms of immune complex GN in HIV infection are  
- IgA nephropathy  
- Hepatitis –  C Virus (HCV) related renal disease  
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HIV has been implicated as a stimulus for immune complex formation 
in IgA nephropathy; immune complexes with HIV antigen have been 
identified in the circulation and renal tissue eluates of HIV infected patients 
with IgA nephropathy and with other immune complex GN .  
HIV – associated immune mediated renal disease usually presents 
with  
- Mild to no renal insufficiency  
- Low grade proteinuria and hematuria  
- Patients rarely progress to ESRD  
The exception is HCV – cryoglobulinemic GN.  
HCV infection is almost universal in HIV patients with a H/o IVDU 
HCV associated cryoglobulinemic GN presents with  
- Nephrotic syndrome (Membrano proliferative GN) 
- Hypertension  
- Purpura  
- Arthralgias  
- Peripheral neuropathy  
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- Depressed complements levels  
- Circulating cryoglobulins 
-   Rapidly progressive renal insufficiency  
- respond to treatment with interferon - α  
The association of membranous nephropathy in HIV-infected patients 
may be explained by the high incidence of HBV infection, malignancies and 
syphilis in this population .  
Other renal diseases reported less commonly include  
- Minimal change disease  
- Amyloidosis  
- Hemolytic urenic syndrome  
- Tumour invasion of the kidneys   
(C) End-Stage Renal Disease (ESRD) 
 HIVAN has become the third leading cause of ESRD among African 
Americans aged 20-64 yrs .[ref4]. 
 Management options for these patients include  
- Hemodialysis  
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- Peritoneal dialysis  
- Transplantation  
Each modality has advantages and disadvantages.  
(i) Improved survival of the HIV positive ESRD patient: In HIV infected 
population, ART has led to dramatic improvements in survival. However, 
the improvement in survival seems to be attenuated in HIV patients with 
ESRD . 
(ii) HIV infected patients dialysed  at San Francisco General Hospital,[ref17].  
CD4 counts  Survival  
> 200 cells /µl 33.4 months  
< 200 cells <µl 7.7 months  
 
Currently there is no reason to withhold renal replacement therapy 
from patients solely on the basis of HIV infection .  
(ii) Hemodialysis: 
- Most common modality for HIV patients  
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- Disadvantage includes 
o Risk of infections from temporary catheters and grafts  
o Risk to dialysis providers of blood and needle stick exposure  
(iii) Infection control in Hemodialysis:  
1. Careful adherence to universal body substance precautions by dialysis 
providers.  
2. Routine infection control precaution and routine cleaning with sodium 
hypochlorite solution of dialysis equipment and of surfaces that are 
frequently touched are sufficient.  
3. Isolation of HIV infected patients from other dialysis patients are 
unnecessary and could violate medical confidentiality.  
4. Dialysate should be treated as a potentially contaminated body fluid.  
The size of the HIV particle is much larger than most dialyzers 
membrane pore sizes; therefore, the HIV particle most likely does not cross 
the dialyzer membrane into dialyzate or ultrafiltrate.  
(iv) Peritoneal dialysis: 
Peritoneal dialysate fluid should be handled as a contaminated body fluid .  
 
 44 
 
Advantages  
• Reduced T-cell activation and cytokine release (Mediators of HIV 
proliferation) attributed to hemodialysis membrane.  
• Enhanced humoral immune function.  
• Improved nitrogen balance from glucose absorption. 
• Permits larger doses of antiretroviral agents in patients with membrane 
associated leukopenias.   
• Higher average hematocrit  
• Lower risk of transmitting HIV infection. 
(v) Medical Management: 
 The standard Dialysis Outcome Quality Initiative (DOQI) 
recommendations should be followed for HIV-infected patients with ESRD .  
• HIV patients with ESRD respond well to erythropoietin therapy. 
• HCV coinfection is very common in HIV infected ESRD patient. 
HIV/HCV coinfected patients should be discouraged from alcohol use and 
should be vaccinated for Hepatitis A and B 
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AIMS AND OBJECTIVES 
TO DETERMINE THE RENAL FUNCTION ABNORMALITIES IN 
PATIENTS WITH HIV INFECTION / AIDS  
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MATERIALS AND METHODS 
Setting: All HIV patients who were attending ART centre and patients                    
admitted in STD ward,GRH,Madurai. 
Collaborating  Departments  : Anti retroviral therapy centre 
                                                     Department of STD  
                                                     Madurai Medical College                                                   
                                                         Madurai.                                             
  
Design of the study   :Cross sectional study 
Period of study   :01.05.2008 – 31.10.2008. 
Sample size        :145 
Ethical committee approval      : obtained  
Consent                   :Informed consent was obtained 
Financial support      : Nil  
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Selection and Details of Study Subjects 
145 HIV patients who were attending ART centre and Dept of STD Govt. 
Rajaji Hospital during the period from 01.05.2008. to 31.10.2008 were included 
in study . 
Inclusion criteria 
All HIV patients attending ART centre and HIV positive patients admitted as 
inpatients in Dept.  of STD were taken for study. 
Exclusion Criteria 
1. Patients with pre-existing hypertension , diabetes mellitus , chronic 
kidney disease , chornic liver disease , coronary artery disease and 
on nephrotoxic drugs were excluded from the study . 
2. Conditions that likely to produce Proteinuria  like  acute  febrile 
illness, pneumonia were exculed from the study. 
3. Only Adult patients were included and patients with age < 12 years    
excludedfromstudy.                                                                           
The total number of cases screened were 250 of which 105 cases 
were  excluded  from  the study. After exclusion of these patients, 
the total number of patients who were taken up for study was 145. 
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 145 patients were grouped into patients with elevated renal           
parameters (Sr.Creatinine >1.5 mg/dL) and without elevated 
renalparameters.                                                                                                      
All the patients in the study were not on Anti retrovival therapy or any 
other medications for Tuberculosis.                                                       
Most patients were on Prophylactic therapy with cotrimoxazole for 
pneumocystis jirovecii pneumonia prophylaxis and on Tab.Fluconazole 
for oral candidiasis. 
        These patients were investigated with Blood samples for Blood Urea, 
Sr.Creatinine , Serum electrolytes, Urine for spot PCR and 24 hrs urinary 
protein excretion and ultrasonography of abdomen for kindney size and for 
other abdominal organ pathology. 
        The collected data was analysed using epidemiological information 
package 2002[EPI 2002] developed by centre for Disease control (CDC) 
Atlanta in colloboration with WHO. Chi square test was used for test of 
significance. The data was compared with previous literatures. 
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RESULTS AND OBSERVATIONS 
 
A: PROFILE OF CASES STUDIED 
 
Table 1 : Age Distribution 
 
RF cases Non RF cases 
Age Group 
No % No % 
< 20 years 1 2.2 1 1 
21-30 11 24.4 29 29 
31-40 25 55.6 50 50 
41-50 6 13.3 14 14 
Above 50 2 4.4 6 6 
Total 45 100 100 100 
Mean 35.7 34.9 
SD 8.3 8.7 
‘p’ 0.4512 Not Significant 
 
In our study 145 patients were analysed, who were grouped into patients with 
HIV infection/AIDS  
with elevated renal parameters (serum creatinine > 1.5mg/dl) and  
without elevation of serum creatinine (<1.5mg/dl). 
Analysing the above table, 
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Out of 145 patients  
2.4% of patients belong to less than 20 yrs of age, 
 28% belong to 21-30 yrs,  
52% belong to 31-40 yrs,  
14% belong to 41-50 yrs, .3.6% belong to more than  50 yrs. 
 The mean age distribution was 35.3. with insignificant ‘p’ value. 
 
Table 2 : Sex Distribution 
 
RF cases Non RF cases 
Sex 
No % No % 
Male 33 73.3 61 61 
Female 12 26.7 39 39 
Total 45 100 100 100 
‘p’ 0.219 Not Significant 
 
In our study 64.8% were males and 35.2%were females with insignificant ‘p’ 
value. 
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Table 3 : Quantitative Parameter 
 
 
RF cases Non RF cases 
Variable 
Mean SD Mean SD 
‘P’ Significant
Urine Spot PCR 2.18 0.75 1.3 0.64 0.0001 Significant
Creatinine 
Clearance 
19.9 9.11 98.2 9.29 0.0001 Significant
24 hours Urinary 
Protein 
1.93 1.03 0.3 0.32 0.0001 Significant
Serum Na 125.4 6.5 138.9 5.6 0.0001 Significant
Serum K 5.16 0.67 4.12 0.53 0.0001 Significant
CD4 Count 132.4 99.3 396.5 172.4 0.0001 Significant
 
 
 
The mean urine spot PCR,24 hrs urine protein excretion was elevated in renal 
failure group compared to non renal failure group with significant ‘p’ value.  
There was hyponatremia and hyperkalemia in renal failure group compared with   
non renal failure group with significant ‘p’ value. 
The mean CD4  count was <150 in renal failure group and The mean CD4 count 
was <400 in non renal failure group. 
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Table 4 : Quantitative Parameter 
RF cases Non RF cases 
Variable 
Mean SD Mean SD 
‘p’ Significance 
Urine Spot PCR 
Normal(.2) 0 0 0 0 
Abnormal (>.2-3) 41 45.6 100 100 
Nephrotic range (>3)  4 8.9 - - 
0.0001 Significant 
Creatinine Clearance(ml/min) 
Stage0-- >90 - - 93 93 
 stageII 60-89 - - 7 7 
 stageIII 30-59 6 13.3 - - 
  stageIV15-29 25 55.6 - - 
  stageV< 15 14 31.1 - - 
0.0001 Significant 
24 Hour Urinary Protein(gms/day) 
  <= 0.15 - - 64 64 
  0.16-1 10 22.2 36 36 
  1-3.5 31 42.2 - - 
 >=3.5 4 35.6 - - 
0.0001 Significant 
Sodium 
Normal 3 93.3 28 28 
Hypo 42 6.7 59 59 
0.0001 Significant 
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Analysing the tables  
24 hrs urine protein excretion in renal failure group—10 pts had <1gm/day 
                                                                                        31pts had>1-<3.5gm/day 
                                                                                        4 pts in nephrotic range. 
In non renal failure group --  normal protein excretion in        64 pts 
                                               Protein excretion<1gm/day in  36pts 
With significant ‘p’ value between two groups. 
 
Creatinine clearance – in RF group – stage III    (30-59) in 6   pts 
                                                            Stage IV   (15-29)  in 25 pts  
                                                            Stage  V      (<15)   in  14 pts 
                                    
                                   In non-RF group—normal   (>90)    in 93 pts 
                                                                   Stage II(60-89) in 7 pts 
Potassium 
Normal 19 2.2 100 17 
Hyper 26 57.8 - - 
0.0001 
 
 
Significant 
 
 
USG Abdomen 
Normal Study - - 67 67 
Bil. Renomegaly 45 100 33 33 
0.0001 Significant 
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Significant hyponatremia and hyperkalemia seen in RF group compared to non-
RF group with significant  “p” value.                                              
Bil.renomegaly present in all cases of RF group and 33 pts in non-RF group 
with significant “p” . 
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Table 5 : Creatinine Clearance Stage and CD4 Count 
 
 
CD4 Count Creatinine 
Clearance(ml/mt) 
Stage(ml/mt) Mean SD 
>90 402.8 176.5 
60-89 312 61.3 
30-59 116.5 30.9 
15-29 147.3 116.9 
<15 112.7 82.7 
‘p’ 
0.0001  
Significant 
 
 
 
 
The mean CD4 count in pts with stage III(30-59)—stage V(<15) --<150 cells. 
Showing increased  risk for renal failure in HIV pts with reduction  in CD4 
count. 
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Table 6:   24 Hours Urinary Protein and CD4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   This table shows increased proteinuria with decreased CD4 count 
 
 
 
 
 
 
CD4 Count 24 Hours 
Urinary Protein 
(gms/day) 
 
Mean SD 
< 0.15 396.3 162.6 
0.16-1 366.7 189.2 
 >1-<3.5 125.4 20.3 
 >=3.5 62.2 19.5 
‘p’ 
0.0001  
Significant 
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DISCUSSION AND COMPARATIVE ANALYSIS 
 
                      In our study 145HIV seropositive patients were analysed for renal 
function abnormalities and compared with the available literature. The age 
incidence showed a median age of 35.3 yrs. 2.4% of patients belong to less than 
20 yrs, 28% belong to 21-30 yrs, 52% belong to 31-40 yrs, 14% belong to 41-50 
yrs, 3.6% belong to more than 50 yrs. 
                   The age wise prevalence in India(AIDS AND HIV 
INFORMATION AVERT.org) 4% in less than 20 yrs, 24% belong to 21-30 yrs, 
35% belong to 31-40 yrs, 27% belong to 41-50 yrs, 15% belong to more than 50 
yrs. HIV prevalence in India is 3.6%. the prevalence for adult female is 0.29% 
and for males 0.43% 
                   In our study  64.8% were males and 35.2% were females with 
insignificant ‘p’ value. In our study, both renal failure group and non renal 
failure group had  proteinuria  with mean spot PCR of 2.18 for RF group and a 
mean of 1.3 for Non-RF group with significant ‘p’ value. 
                  24 hours urine protein excretion had a mean of 1.93gm/day for RF 
group 0.3gm/day for Non-RF pts.with significant increase of  proteinuria in pts. 
With renal failure. 
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• Nearly 100% pts. in RF group had increased proteinuria and 36% of pts 
in non-RF group had proteinuria. 
• The overall (RF& Non-RF)  percentage of pts with proteinuria was 
55.86% with 31.7% pts with less than 1gm/day. 
• No pts in Non-RF group had proteinuria more than 1 gm/dayor nephrotic 
range (>=3.5 gm/day). 
• In RF group 21.4% had proteinuria >1gm/d-<3.5 gm/d. 0.09% had 
nephrotic range proteinuria. 
• Proteinuria was increased in RF group in comparision to non-RF group 
with significant ‘p’ value. 
• Patients with normal24 Hrs. proteinuria had a mean CD4 cell count of 
396.3 cell/micL. 
• Pateints with proteinuria less than 1gm/day had mean CD4 count of 366.7 
cells/micL. 
• Patients with more than 1gm/day and less than 3.5 gm/day had mean CD4 
of 125.4 and pts. with nephrotic range had 62.2 cells/micL. 
• In Sczezch et al study,32% had proteinuria. The predictors of proteinuria 
in his study was 
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• Absolute CD4 count <= 200cells/micL. and high HIV RNA level. This 
study establishes association between decreasing CD4 count and high 
HIV RNA levelwith the presence of proteinuria and occurrence of renal 
failure. 
           Han et al reported 24% of HIV pts with persistent microalbuminuria 
were proved to be having HIVAN by renal biopsy. Renal biopsy may be 
considered in HIV patients with persistent microalbuminuria with low CD4 
count irrespective of good renal function. 
           In our study nephrotic range proteinuria was seen in 4 patients ( 0.09%) 
of RF group.All these pts. Had high serum creatinine value (mean 4.4mg/dL) 
and low CD4 count (mean- 45 cells/micL)  with mean serum creatinine 
clearance of 12.84 mL/min showing association between increasing proteinuria 
with low CD4 count ,high serum creatinine and reduced creatinine clearance 
consistent with above study. 
           Alma et al conducted a study to document the histopathologic diagnosis 
in HIV pts with and without nephrotic range range proteinuria  and to evaluate 
the predictive value of both nephrotic range proteinuria and CD4 count in 
diagnosing HIVAN. 
 60 
 
                In his study 53% of biopsy proven HIVAN had nephrotic range 
proteinuria . the patients with HIVAN had significantly higher serum creatinine 
(8.2 mg/dL)and lower CD4 count       (158cells/micL ) at the time of biopsy. 
                Shri Ganesh R Barnela et al, study with 102 pts renal dysfunction in 
39.21%. 19.6% had proteinuria of which 8.82% had nephrotic range proteinuria 
, HIVAN in 5.8%. 
                 In our study,hyponatremia was seen in 93% of pts in RF group and 
59% of pts in non-RF group. Overall 69.6% pts had hyponatremia .The mean 
serum sodium in RF group was 125.4 and in non-RF group was 138.9 with 
significant ‘p’ value. 
                  In our  study, hyperkalemia was present in 55% of  RF group. No pts 
in non-RF had hyperkalemia.The mean serum potassium in RF group is 5.16 
and in non-RF 4.12 Both hyponatremia and hyperkalemia occur commonly due 
to vomiting or diarrhoea. May also be manifestation of mineralocorticoid 
deficiency resulting from adrenal insufficiency or the syndrome of 
hyporeninemic hypoaldosteronism. 
                  Perazalla MA, Wright FS et al described hyperkalemia in patients on 
Trimethoprim/sulfamethoxazole Prophylaxis . Trimethoprim may act like 
amiloride and blocks apical membrane sodium channels in the distal nephron.               
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                  Decreased potassium excretion leads to hyperkalemia in substantial 
number of patients treated with trimethoprim containing drugs. 
                 In our study creatinine clearance had a mean of 19.9mL/min in RF 
group and 98.2mL/min in non-RF group. 
                 The analysis between 24 hours urine protein ,serum creatinine , 
creatinine clearance and CD4 count showed a correlation of increased 
proteinuria with high serum creatinine , low CD4 count and reduced creatinine 
clearance. Mocroft A, Kirk et al showed 3.5% with end stage renal diseasehad 
lower CD4 cell count (median-80 vs 137 cells/micL). 
In our study CD4 count in pts in  
                                          stage III CKD—116.5 cells 
                               Stage IV CKD—147.3 cells 
    Stage V CKD—112.7 cells 
                    All patients in RF group were in stage III to stage V with mean 
CD4 count of 125.5 showing clearly the risk of progressive renal failure with 
lower CD4 count. 
In Non-RF group , the creatinine clearance was stage 0(>90ml/min)—stage II 
(60-89ml/min) with  mean CD4 count in stage 0-402.8cells/micL 
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                stage II-312cells/micL showing decreased creatinine clearance with  
lower CD4 count . 
                In our study, ultrasound abdomen showed bilateral enlarged kidneys 
in all (100%) patients with renal failure and 33% of non-renal failure group. 
Overall percentage of patients with bilateral enlarged kidneys was 53.8%. 
                  Di Forti et al study showed 20% of HIV associated nephropathy 
patients with bilateral enlarged kidneys and 38% with decreased cortico 
medullary differentiation. In his study increased echogenicity and a 
heterogenous echopattern were the most common finding seen in 75% of cases. 
Globular morphology and loss of renal sinus fat in about half of patients. 
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CONCLUSION 
1. The presence of proteinuria in our study group was 55.86% 
 
2. Patients with high proteinuria had high serum creatinine values and low 
CD4 (< 150 cells) count and reduced creatinine  clearance. 
 
 
3. Nephrotic range proteinuria was present in 0.09%  of HIV seropositive  
patients  with CD4 count =< 50 cells/micL. 
 
4. Bilaterally enlarged kidneys were present in 53.8% of patients with 
increased proteinuria. 
 
 
Limitations:   
In our study only small number of patients (145) were involved and since it 
was a cross sectional study , the causal relatioship could not be identified 
using a cross sectional analysis. 
Renal biopsy  could not be done because of ethical problems. 
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SUMMARY 
 
           The study “ A STUDY OF RENAL FUNCTION 
ABNORMALITIES IN PATIENTS WITH HIV INFECTION/ AIDS” was 
done in 145 patients who were attending the Antiretroviral Therapy centre and 
patients who were admitted as inpatients in Department of STD, Govt. Rajaji 
Hospital, Madurai. Selected patients were divided in to two groups , patients 
with Renal failure (sr.creatinine>1.5mg/dl)  and without Renal failure 
(<1.5mg/dl). 
                     Selected patients were subjected to urine analysis for proteinuria 
with urine for spot PCR, 24 hours urine protein excretion. Blood investigations 
for blood urea,serum creatinine, serum electrolytes and ultrasound abdomen for 
kidney size.Out of 145 patients, 2.4% belong toless than 20 yrs, 28% belong to 
21-30 yrs,52% belong to 31-40 yrs,14% belong to 41-50yrs and 3.6% belong to 
above 50 yrs. 
                     In our study 64.8% were males and 35.2% were 
females.Proteinuria was present in 55.86% of patients with 31.7% with less than 
1gm/day.21.4% of patients had proteinuria more than 1gm/day but less than 3.5 
gm/day 0.09% had nephrotic range proteinuria. 
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                    No patients in Non renal failure group had proteinuria more than 
1gm/day or nephrotic range proteinuria .CD4 cell count in patients with normal 
24 hours protein excretion showed mean CD4 cell count of 396.3 cells.Patients 
with less than 1gm/day of proteinuria had a mean of 366.7 cells.Patients with 
more than 1gm/day and less than 3.5 gm/day had a mean of125.4 cells. 
                    Patients with nephrotic range proteinuria had mean CD4 count of 
62.2 cells.The above data analysis shows significant relationship between high 
proteinuria and low CD4 count. 
                    In our study analysis of proteinuria, serum creatinine, creatinine 
clearance and CD4 cell count showed increased proteinuria with high serum 
creatinine , low CD4 count and decreased creatinine clearance. Ultrasound 
abdomen showed bilaterally enlarged in patients with high proteinuria .53.8% of 
patients in our study showed bilaterally enlarged kidneys. 
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GLOSSARY 
ADH -Anti Diuretic Hormone 
AER -Albumin Excretion Rate 
AIDS   -Acquired Immunodeficiency Syndrome 
ARF    -Acute Renal Failure 
ART   -Antiretroviral Therapy 
ATN   -Acute Tubular Necrosis 
CDC   -Centre For Disease Control 
DNA -Deoxy RiboNucleic Acid 
ECF   -Extra Cellular Fluid 
ELISA   -Enzyme Linked Immunosorbent Assay 
ESRD   -End Stage Renal Disease 
GRH   -Government Rajaji Hospital 
HIV    -Human Immunodeficiency Virus 
HIVAN  -Human Immunodeficiency Virus Associated Nephropathy 
IDU -Injection Drug Users 
KS   -Kaposi’s Sarcoma 
MPGN -Membrano Proliferative Nephropathy 
NSAIDS  -Non Steroidal Anti Inflammatory Agents 
RF -Renal Failure 
RNA   -RiboNucleic Acid 
SIADH -Syndrome of Inappropriate Anti Diuretic Hormone Secretion 
Spot PCR -Spot Protein Creatinine Ratio 
Tg26 -Transgenic Mice 
TRI -Tubulo Reticular Inclusions 
UNAIDS  -Joint United Nations Programme on HIV/ AIDS 
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PROFORMA 
 
Sl.No    : 
Name    : 
Age / Sex    :    IP. No : 
Address    : 
 
Socioeconomic Status : 
Disease Status - HIV-1 / HIV -2 / AIDS 
CD4 count  -   CD4 % : 
Height:                                                   Weight: 
Blood Pressure  - 
CLINICAL DETAILS: 
 
INVESTIGATIONS: 
Urine - Spot Protein / Creatinine Ratio: 
Urine -  Albumin:                           Sugar  :                                       Deposit: 
24 Hrs. Urine protein: 
 
Blood - Sugar:                                                   Urea: 
 
 71 
 
Sr. Creatinine - 
 
Sr. Electrolytes –    Na  : 
    K  : 
    HCO3 : 
             Cl  : 
 
USG. Abdomen & Pelvis : 
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The above graph shows lower CD4 COUNT (<200 cells) in 
patient with renal failure 
Serum
Na K HCO3 Cl
1 40 M 0.3
Alb(+)     
N         
N
95.5 0.032 32 0.8 135 4.3 23 110 Normal study
2 35 F 0.5
Alb(+)     
N         
N
94 0.035 28 0.8 140 3.6 18 102 Normal study
3 32 M 0.45
Alb(+)     
N         
N
112.5 0.135 36 0.9 138 4.2 20 106 Normal study
4 33 M 0.8
Alb(+)     
N         
N
91.5 0.045 40 1 142 4.8 22 110 Normal study
5 24 F 2.5
Alb(++)    
N         
N
93.5 0.850 35 0.7 128 5 17 104 Bil.renomegaly
6 27 M 2.2
Alb(++)    
N         
N
110 0.950 38 1 130 4.5 22 115
Bil.renomegaly  , 
Ascites,      
Bil.pleural effusion
7 32 M 0.55
Alb(+)     
N         
N
112.5 0.038 40 0.8 139 4.4 19 98 Normal study
8 40 M 0.9
Alb(+)     
N         
N
98.5 0.082 26 0.8 142 4.9 20 102 Normal study
9 32 M 2
Alb(++)    
N         
N
101.5 0.750 32 0.9 132 5 17 110 Bil.renomegaly
10 24 F 0.28
Alb(+)     
N         
N
99 0.080 29 0.8 137 3.9 21 105 Normal study
11 33 M 0.3
Alb(-)      
N         
N
98.5 0.075 33 0.9 147 4.7 20 100 Normal study
12 22 F 0.85
Alb(-)      
N         
N
100.5 0.035 38 0.8 138 3.9 22 96 Normal study
13 27 F 0.35
Alb(-)      
N         
N
97.5 0.055 35 0.9 146 3.8 19 112 Normal study
14 32 M 0.5
Alb(-)      
N         
N
98 0.075 30 0.7 138 4.3 18 106 Normal study
15 33 M 0.45
Alb(-)      
N         
N
94.5 0.065 31 0.9 135 3.4 20 95 Normal study
16 60 F 2.75
Alb(++)    
N         
N
97.5 0.850 33 0.8 125 4.5 22 99 Bil.renomegaly
17 42 F 0.35
Alb(+)     
N         
N
93.5 0.086 24 0.8 143 5 21 104 Normal study
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S.No. Age Sex USG Abd.
urine 
spot 
PCR
Urine  Alb. 
Sug.  
Dep/HPF
18 30 F 2
Alb(++)    
N         
N
91.5 0.900 36 0.9 138 4 17 110 Bil.renomegaly
19 43 M 1.2
Alb(+)     
N         
N
98.5 0.015 34 0.7 136 3.3 18 94 Normal study
20 31 F 2.5
Alb(++)    
N         
N
105.5 0.875 28 1 137 4.6 24 97
Bil.renomegaly  , 
Ascites,      
Bil.pleural effusion
21 35 M 1.8
Alb(++)    
N         
N
98.5 0.950 32 0.9 130 4.2 23 106   Bil.renomegaly
22 38 M 0.3
Alb(+)     
N         
N
103.3 0.085 38 0.8 143 3.4 21 108 Normal study
23 52 M 1.9
Alb(++)    
N         
N
109 0.500 40 0.8 141 4.4 19 112 Bil.renomegaly
24 40 F 1.75
Alb(++)    
N         
N
105 0.750 33 0.8 137 4.7 20 114 Bil.renomegaly
25 35 M 1.1
Alb(+)     
N         
N
90.5 0.080 36 1 149 3.9 18 103 Normal study
26 40 F 1.2
Alb(-)      
N         
N
92 0.090 39 1 140 3.4 24 109 Normal study
27 55 M 0.3
Alb(-)      
N         
N
91 0.018 30 0.8 139 3.8 21 116 Normal study
28 33 M 1.2
Alb(-)      
N         
N
100.3 0.090 27 0.8 135 3.5 19 103 Normal study
29 36 M 0.8
Alb(-)      
N         
N
112 0.150 29 1 143 4.6 17 100 Normal study
30 35 F 0.5
Alb(-)      
N         
N
107 0.038 34 0.9 146 4 22 105 Normal study
31 40 M 1.5
Alb(+)     
N         
N
98 0.050 38 0.9 145 3.8 20 109 Normal study
32 30 F 1.25
Alb(++)    
N         
N
113 0.360 40 1 141 4.9 17 113 Bil.renomegaly
33 21 F 1.8
Alb(-)      
N         
N
112 0.030 37 0.8 139 3.7 22 104 Normal study
34 40 M 0.9
Alb(+)     
N         
N
97 0.080 40 1 140 4.8 18 112 Normal study
35 25 M 1.2
Alb(-)      
N         
N
109 0.015 36 1 146 4.5 23 109 Normal study
36 26 F 1.75
Alb(++)    
N         
N
105 0.450 35 0.9 133 4.5 21 96 Bil.renomegaly
37 36 F 0.8
Alb(+)     
N         
N
93 0.150 33 0.9 147 3.2 19 100 Normal study
38 35 F 1.5
Alb(++)    
N         
N
95 0.950 39 0.7 136 3.7 18 97 Bil.renomegaly
39 21 F 1.8
Alb(+)     
N         
N
109 0.065 28 0.9 144 3.5 20 115 Normal study
40 35 F 1.8
Alb(++)    
N         
N
97 0.780 32 0.7 125 5 24 103
Bil.renomegaly, 
Ascites,      
Bil.pleural effusion
41 35 M 0.9
Alb(-)      
N         
N
93.3 0.098 39 1 140 3.3 17 106 Normal study
42 37 M 0.45
Alb(-)      
N         
N
97.6 0.076 35 0.7 138 4.1 22 108 Normal study
43 45 F 1.3
Alb(-)      
N         
N
91.5 0.140 32 0.9 135 4.7 19 102 Normal study
44 33 M 1.5
Alb(-)      
N         
N
93.8 0.100 37 0.8 133 4.9 21 98 Normal study
45 32 M 1.5
Alb(-)      
N         
N
95.3 0.135 23 0.7 145 4.5 22 96 Normal study
46 25 F 0.85
Alb(+)     
N         
N
93.5 0.125 31 0.9 135 3.6 20 114 Normal study
47 32 M 1
Alb(+)     
N         
N
98.3 0.450 29 0.9 139 3.9 18 105 Bil.renomegaly
48 45 M 1.5
Alb(++)    
N         
N
91.5 0.550 33 0.8 138 4.2 23 95 Normal study
49 29 M 0.8
Alb(+)     
N         
N
112.3 0.140 27 0.9 136 4.2 19 100 Normal study
50 39 F 1.9
Alb(+)     
N         
N
94.3 0.460 39 0.7 139 3.6 17 94 Bil.renomegaly
51 34 M 0.76
Alb(+)     
N         
N
91.4 0.145 35 1 145 4.7 21 95 Normal study
52 35 M 0.85
Alb(+)     
N         
N
94.5 0.130 40 0.9 140 4.3 23 100 Normal study
53 26 F 1.75
Alb(++)    
N         
N
105.3 0.550 39 0.8 134 4 19 110 Bil.renomegaly
54 25 M 1.8
Alb(++)    
N         
N
110.4 0.600 33 0.7 125 4.8 20 112 Bil.renomegaly
55 23 F 2.2
Alb(++)    
N         
N
107 0.970 27 0.8 143 3.5 22 114 Bil.renomegaly
56 24 F 0.9
Alb(-)      
N         
N
113 0.086 29 1 147 4.5 16 104 Normal study
57 25 M 1.5
Alb(-)      
N         
N
112 0.090 33 0.8 148 3.9 22 109 Normal study
58 53 M 1.2
Alb(-)      
N         
N
94 0.135 37 0.9 145 4.2 19 106 Normal study
59 30 M 1.8
Alb(-)      
N         
N
105 0.140 30 1 139 3.7 18 110 Normal study
60 32 M 0.3
Alb(-)      
N         
N
103 0.035 35 1 135 3.2 23 98 Normal study
61 25 M 0.6
Alb(+)     
N         
N
110 0.050 34 0.8 147 3.9 21 95 Normal study
62 45 M 1.75
Alb(++)    
N         
N
93 0.850 39 0.8 142 3.6 17 102 Bil.renomegaly
63 42 M 1.5
Alb(++)    
N         
N
91.3 0.650 31 0.9 132 4.8 20 105 Bil.renomegaly
64 27 F 1.6
Alb(+)     
N         
N
103 0.075 37 0.9 134 5 22 110 Normal study
65 32 M 1.2
Alb(+)     
N         
N
95 0.090 40 1 140 3.5 21 106 Normal study
66 37 M 1.5
Alb(+)     
N         
N
94 0.135 32 0.9 142 4 17 112 Normal study
67 41 M 0.9
Alb(+)     
N         
N
92 0.145 29 0.8 149 3.2 22 115 Normal study
68 32 M 1.5
Alb(++)    
N         
N
98 0.950 38 0.7 146 3.9 20 106 Bil.renomegaly
69 42 M 0.85
Alb(+)     
N         
N
91 0.100 30 0.8 145 3.6 18 102 Normal study
70 36 M 1.8
Alb(++)    
N         
N
93 0.875 39 0.8 136 4.7 19 115 Bil.renomegaly
71 44 M 1.4
Alb(-)      
N         
N
90.5 0.080 40 0.9 129 4.5 24 99 Normal study
72 36 M 0.65
Alb(-)      
N         
N
92 0.075 29 0.7 142 4.2 20 107 Normal study
73 25 F 1.2
Alb(-)      
N         
N
98 0.095 33 1 135 4 19 110 Normal study
74 35 M 1.5
Alb(-)      
N         
N
91 0.090 37 0.8 139 3.7 21 115 Normal study
75 30 F 0.9
Alb(-)      
N         
N
110 0.085 39 0.7 145 3.5 22 100 Normal study
76 41 M 1.5
Alb(+)     
N         
N
93 0.135 40 0.8 138 5 24 102 Normal study
77 65 M 1.6
Alb(+)     
N         
N
66.5 0.125 30 0.9 146 4.3 23 108 Normal study
78 50 F 1.85
Alb(++)    
N         
N
91 0.775 34 0.9 131 3.3 18 96
Bil.renomegaly, 
Ascites,      
Rt.pleural effusion
79 35 M 0.5
Alb(+)     
N         
N
93 0.140 29 0.8 139 3.7 20 108 Normal study
80 25 F 1.65
Alb(++)    
N         
N
107 0.900 31 0.7 133 3.8 22 110 Bil.renomegaly
81 23 F 0.85
Alb(+)     
N         
N
110 0.100 35 1 136 3.4 19 115 Normal study
82 37 M 2.5
Alb(++)    
N         
N
98 0.250 30 0.8 144 3.9 17 104 Bil.renomegaly
83 30 M 2.3
Alb(++)    
N         
N
107 0.350 29 0.9 138 4.1 22 100 Bil.renomegaly
84 31 M 0.8
Alb(+)     
N         
N
109 0.140 40 0.7 136 4.5 17 96 Normal study
85 47 M 1.4
Alb(+)     
N         
N
93 0.120 39 0.8 132 4.8 23 105 Normal study
86 28 M 1.8
Alb(-)      
N         
N
99 0.080 31 0.9 146 4.3 21 110 Normal study
87 32 M 1.3
Alb(-)      
N         
N
102 0.075 29 0.7 141 3.9 24 100 Normal study
88 34 F 0.9
Alb(-)      
N         
N
106 0.085 37 0.8 145 5 19 95 Normal study
89 18 M 1.2
Alb(-)      
N         
N
112 0.095 40 0.9 140 3.8 22 98 Normal study
90 28 F 0.5
Alb(-)      
N         
N
99 0.075 29 0.7 135 4.3 20 110 Normal study
91 38 M 1.65
Alb(++)    
N         
N
87 0.750 33 0.8 136 4.6 19 106 Bil.renomegaly
92 38 M 2.2
Alb(+)     
N         
N
85 0.325 37 0.9 142 3.6 18 105 Normal study
93 31 M 2.5
Alb(++)    
N         
N
89 0.450 27 0.8 144 3.6 20 110 Bil.renomegaly
94 41 M 2.8
Alb(++)    
N         
N
85 0.550 31 0.7 128 4.8 18 102 Bil.renomegaly
95 40 F 2
Alb(++)    
N         
N
90 0.850 29 0.9 130 4.2 22 108
Bil.renomegaly, 
Ascites,        
Bil.pleural effusion
96 39 F 2.3
Alb(++)    
N         
N
95 0.755 38 1 135 3.8 20 97 Bil.renomegaly
97 42 F 0.9
Alb(+)     
N         
N
93 0.100 33 0.8 140 3.5 18 110 Normal study
98 27 F 1.8
Alb(++)    
N         
N
113 0.950 35 0.9 142 4 22 95 Bil.renomegaly
99 58 F 0.8
Alb(+)     
N         
N
67 0.160 30 0.7 138 3.5 20 110 Normal study
100 40 F 2.2
Alb(++)    
N         
N
69 0.800 47 0.8 145 5 16 115 Bil.renomegaly
CD4 COUNT
217
364
701
281
238
342
229
237
247
270
376
678
240
376
428
442
289
475
441
209
327
344
344
549
310
753
399
269
331
323
460
559
628
280
511
357
354
274
293
384
292
679
163
576
693
896
487
209
363
225
480
274
509
275
498
463
499
525
346
421
284
1225
259
617
377
339
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